PMID- 32528903
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20220531
IS  - 2235-2988 (Electronic)
IS  - 2235-2988 (Linking)
VI  - 10
DP  - 2020
TI  - Plasmacytoid Dendritic Cells as Cell-Based Therapeutics: A Novel Immunotherapy to 
      Treat Human Immunodeficiency Virus Infection?
PG  - 249
LID - 10.3389/fcimb.2020.00249 [doi]
LID - 249
AB  - Dendritic cells (DCs) play a critical role in mediating innate and adaptive 
      immune responses. Since their discovery in the late 1970's, DCs have been 
      recognized as the most potent antigen-presenting cells (APCs). DCs have a 
      superior capacity for acquiring, processing, and presenting antigens to T cells 
      and they express costimulatory or coinhibitory molecules that determine immune 
      activation or anergy. For these reasons, cell-based therapeutic approaches using 
      DCs have been explored in cancer and infectious diseases but with limited 
      success. In humans, DCs are divided into heterogeneous subsets with distinct 
      characteristics. Two major subsets are CD11c(+) myeloid (m)DCs and CD11c(-) 
      plasmacytoid (p)DCs. pDCs are different from mDCs and play an essential role in 
      the innate immune system via the production of type I interferons (IFN). However, 
      pDCs are also able to take-up antigens and effectively cross present them. Given 
      the rarity of pDCs in blood and technical difficulties in obtaining them from 
      human blood samples, the understanding of human pDC biology and their potential 
      in immunotherapeutic approaches (e.g. cell-based vaccines) is limited. However, 
      due to the recent advancements in cell culturing systems that allow for the 
      generation of functional pDCs from CD34(+) hematopoietic stem and progenitor 
      cells (HSPC), studying pDCs has become easier. In this mini-review, we 
      hypothesize about the use of pDCs as a cell-based therapy to treat HIV by 
      enhancing anti-HIV-immune responses of the adaptive immune system and enhancing 
      the anti-viral responses of the innate immune system. Additionally, we discuss 
      obstacles to overcome before this approach becomes clinically applicable.
CI  - Copyright (c) 2020 van der Sluis, Egedal and Jakobsen.
FAU - van der Sluis, Renee M
AU  - van der Sluis RM
AD  - Aarhus Institute of Advanced Studies, Aarhus University, Aarhus, Denmark.
AD  - Department of Biomedicine, Aarhus University, Aarhus, Denmark.
FAU - Egedal, Johanne H
AU  - Egedal JH
AD  - Department of Biomedicine, Aarhus University, Aarhus, Denmark.
FAU - Jakobsen, Martin R
AU  - Jakobsen MR
AD  - Department of Biomedicine, Aarhus University, Aarhus, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200526
PL  - Switzerland
TA  - Front Cell Infect Microbiol
JT  - Frontiers in cellular and infection microbiology
JID - 101585359
RN  - 0 (CD11c Antigen)
RN  - 0 (Interferon Type I)
SB  - IM
MH  - CD11c Antigen
MH  - *Cell- and Tissue-Based Therapy
MH  - *Dendritic Cells
MH  - *HIV Infections/therapy
MH  - Humans
MH  - Immunotherapy
MH  - Interferon Type I
PMC - PMC7264089
OTO - NOTNLM
OT  - CD8+ T cells
OT  - DC vaccine
OT  - HIV
OT  - HIV latency
OT  - NK cells
OT  - dendritic cells
OT  - pDC
OT  - plasmacytoid DC
EDAT- 2020/06/13 06:00
MHDA- 2021/06/22 06:00
PMCR- 2020/01/01
CRDT- 2020/06/13 06:00
PHST- 2020/02/09 00:00 [received]
PHST- 2020/04/29 00:00 [accepted]
PHST- 2020/06/13 06:00 [entrez]
PHST- 2020/06/13 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fcimb.2020.00249 [doi]
PST - epublish
SO  - Front Cell Infect Microbiol. 2020 May 26;10:249. doi: 10.3389/fcimb.2020.00249. 
      eCollection 2020.